Clinical trials: Nervousness
Epilepsy, Contraception
Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users
The investigators will conduct a prospective, seven-month pilot study to explore pharmacokinetic (PK) and pharmacodynamic (PD) effects among women with epilepsy using the levonorgestrel intrauterine system (LNG IUS) for…
- Trial name
- WESAIL (NCT02362373)
- Testing
- levonorgestrel IUS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Columbia University
Aphasia
Brain Stimulation and Aphasia Treatment
The purpose of this study is to assess the changes in language processing of patients with chronic, post-stroke aphasia following the application of brain stimulation.
- Trial name
- tDCS (NCT01686373)
- Testing
- Activa Dose II Real tDCS
- Where
- 2 sites in United States
- Volunteers
- 74 people
- Sponsor
- University of South Carolina
Stroke, Neurologic Disorder
Evaluation of Bioness Integrated Therapy System (BITS) Touch Screen Technology to Improve Field Awareness
The Bioness Integrated Therapy System (BITS) (Bioness Inc. Valencia, CA) Touch Screen is an FDA approved device comprised of an interactive touchscreen and diverse program options to challenge patients through the use of visual…
- Conditions
- Stroke, Neurologic Disorder, Traumatic Brain Injury, Acquired Brain Injury
- Trial name
- NCT04930822
- Testing
- Table Top Visual Intervention, Bioness Integrated Therapy System Visual Intervention
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Gaylord Hospital, Inc
Metastases, Brain
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
This open label study was designed to evaluate Lapatinib effect on incidence of brain metastases in ErbB2 (HER2) positive metastatic breast cancer patients exposed to prior taxanes or anthracyclines.
- Trial name
- NCT00820222
- Testing
- capecitabine, lapatinib, trastuzumab
- Where
- 164 sites in United States, Belgium and 12 more
- Volunteers
- 540 people
- Sponsor
- Novartis Pharmaceuticals
ALS (Amyotrophic Lateral Sclerosis)
Safety and Feasibility of the EyeControl Device
The EyeControl device is an eye movement-based communication device in the form of wearable glasses with connected infrared cam-era that tracks the pupil and translates blinks and movements into commands.This study is aimed to…
- Trial name
- NCT02891629
- Testing
- EyeControl device
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eyefree Assisting Communication Ltd
Obstructive Sleep Apnea, Excessive Sleepiness
Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA
This trial is a randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of JZP-110 on driving performance in subjects with excessive sleepiness due to obstructive sleep apnea.
- Trial name
- NCT02806895
- Testing
- JZP-110
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- Jazz Pharmaceuticals
Cerebral Palsy
A Study of UCB and MSCs in Children With CP: ACCeNT-CP
The main purpose of this study is to estimate change in motor function 12 months after treatment with a single dose of allogeneic umbilical cord blood (AlloCB) or repeated doses of umbilical cord tissue-derived mesenchymal…
- Trial name
- ACCeNT-CP (NCT03473301)
- Testing
- Infusion of allogeneic umbilical cord blood, Infusion of MSCs
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Joanne Kurtzberg, MD
Stroke, Cerebrovascular Accident (CVA)
The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke
The purpose of this study is to evaluate if 5 consecutive sessions of PathMaker anodal DoubleStim treatment, which combines non-invasive stimulation of the spinal cord (tsDCS- trans-spinal direct current stimulation) and of the…
- Conditions
- Stroke, Cerebrovascular Accident (CVA), Hemiparesis, Spasticity as Sequela of Stroke
- Trial name
- NCT03080454
- Testing
- anodal Doublestim
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Northwell Health
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD)
Duchenne/Becker muscular dystrophy (DMD/BMD) is a genetic disorder that develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function.
- Trial name
- NCT01009294
- Testing
- Ataluren, Chronic Corticosteroid Therapy
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 6 people
- Sponsor
- PTC Therapeutics
Cardiovascular Disease, Hypertension
Stop Atherosclerosis in Native Diabetics Study
Compared to standard treatment goals achieving lower targets for LDL cholesterol (bad cholesterol) and blood pressure in people with diabetes will slow the progression of atherosclerosis as measured by carotid artery thickness…
- Conditions
- Cardiovascular Disease, Hypertension, Hyperlipidemia, Diabetes
- Trial name
- SANDS (NCT00147251)
- Testing
- FDA approved drugs to treat blood pressure and cholesterol
- Where
- 4 sites in United States
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Cynthia West
Diabetes Mellitus, Polyneuropathies
Neurogenic Inflammation in Diabetes
Polyneuropathy is a complication of diabetes mellitus which leads to decreased sensation in arms and legs. This in turn can lead to the development of (infected) foot ulcers.
- Conditions
- Diabetes Mellitus, Polyneuropathies, Arthropathy, Neurogenic
- Trial name
- NCT01370837
- Testing
- Intracutaneous injection of Candida albicans antigen., Temperature measurement.
- Where
- Netherlands
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Postural Orthostatic Tachycardia Syndrome, Chronic Orthostatic Intolerance
Using Mirabegron to Increase BP in Patients With POTS
This is a pilot dose-finding study to test the hypothesis that mirabegron increases systolic blood pressure (BP), prevents syncope/presyncope, and improves the quality of life (QOL), functional capacity, chest pain, and…
- Conditions
- Postural Orthostatic Tachycardia Syndrome, Chronic Orthostatic Intolerance, Syncope
- Trial name
- RAISE-BP (NCT06133075)
- Testing
- Mirabegron 50 MG, Mirabegron 25 MG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Mania
Neurochemical Effects of Omega-3 Fatty Acids in Adolescents at Risk for Mania
The purpose of this study is to see if taking a substance called omega-3 fatty acids is effective, safe, and well-tolerated for treating adolescents with major depressive disorder (also called simply "depression" or "clinical…
- Trial name
- R34 (NCT00917501)
- Testing
- OMega 3
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
Epilepsy, Seizure Disorders
External Trigeminal Nerve Stimulation for Epilepsy
This study investigates a new therapy for epilepsy called Trigeminal Nerve Stimulation (TNS). TNS involves external electrical stimulation of sensory nerve located above the eyes and over the forehead.
- Trial name
- NCT01159431
- Testing
- Trigeminal Nerve Stimulation
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Olive View-UCLA Education & Research Institute
Post Acute Sequelae Covid-19 Hyposmia
Directed Topical Drug Delivery for Treatment for PASC Hyposmia
This is a phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy of topical intranasal treatment of beclomethasone vs. placebo for improved olfactory function.
- Trial name
- NCT05970731
- Testing
- Beclomethasone, Microsponge
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Duke University
Advanced Parkinson's Disease
Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease
The primary objective of this study will be to provide further evidence of the long-term safety and tolerability of levodopa-carbidopa intestinal gel (Duodopa®) over 12-months in participants with advanced Parkinson's disease…
- Trial name
- NCT00335153
- Testing
- Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube
- Where
- 83 sites in United States, Australia and 14 more
- Volunteers
- 354 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Parkinson Disease, Cognitive Impairment, Mild
Speech, Linguistic and Acoustic Markers in Parkinson's Disease
The Investigators aim to identify speech and language markers that provide information on cognitive function and predict cognitive decline in Parkinson's disease.
- Conditions
- Parkinson Disease, Cognitive Impairment, Mild, Speech
- Trial name
- SLAM-PD (NCT04273672)
- Testing
- Cognitive Battery, Voice, Speech and Language Analysis, Questionnaires and Clinical Assessments
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Spinal Cord Injury
Improving Motor Function After Spinal Cord Injury
The goals of this study are to examine the physiology of Central Nervous System pathways contributing to the control of upper and lower extremity movements after SCI, and to promote the recovery of extremity movements by using…
- Trial name
- NCT01915095
- Testing
- rTMS, Training, Motor Task
- Where
- 3 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Diabetic Neuropathy
An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy
The purpose of this study is to determine the efficacy and safety of Perampanel in patients with painful diabetic neuropathy.
- Trial name
- NCT00505284
- Testing
- E2007 (2 mg), E2007 (4 mg), E2007 (6 mg)
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- Eisai Inc.
Hunter Syndrome
A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®
Elaprase (idursulfase), a large molecular protein, is not expected to cross the blood brain barrier at therapeutic levels when administered intravenously.
- Trial name
- NCT00920647
- Testing
- Control, Idursulfase IT (1 mg), Idursulfase IT (10 mg)
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 16 people
- Sponsor
- Shire
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.